Thomas A. Raffin

Tom spent 24 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics and Founder and Director Emeritus of the Stanford University Asia Medical Fund. Tom received the Stanford Medical School RISE Award as alumni of the year in 2014. He has written over 200 articles, chapters and books. Over the past two decades he has worked extensively in the healthcare and medical device sectors and is a co-founder of Rigel Pharmaceuticals. Tom has represented THP on the boards of InvisALERT, Akoya Biosciences (NASDAQ:AKYA), AngioScore (acquired by Spectranetics), Confirma (acquired by Merge), LDR Spine (NASDAQ:LDRH), PneumRx (acquired by BTG Plc), Freedom Innovations (acquired by Health Evolution Partners) and Magstim. He was an observer on the boards of Estech (acquired by AtriCure) and Vidacare (acquired by Teleflex). He is Co-Chairman of the Board of the National AIDS Memorial in Golden Gate Park.

Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and completed his medical residency at the Brigham and Women’s Hospital in Boston.